Physician
Czerkawska-Zydzik, Magdalena
Czerkawska-Zydzik, Magdalena was paid $1.31M by Medicaid between Jan 2018 and Mar 2023, across 38 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoCZERKAWSKA-ZYDZIK, MAGDALENA
SPRINGFIELD, MA 01104
SPRINGFIELD, MA 01104
33aNPI1053308353assigned 10/02/2005
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$1.31M
24GClaims37,768
24DCodes billed38
24AFirst – last monthJan 2018 – Mar 2023
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Massachusetts
Rank by total paid#9 of 54
Median peer was paid$119K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,273 | $251K | |
| 2019 | 9,389 | $292K | |
| 2020 | 6,323 | $230K | |
| 2021 | 5,655 | $203K | |
| 2022 | 7,284 | $266K | |
| 2023 | 1,844 | $66K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 4,407 | 3,885 | $406K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 5,103 | 4,626 | $278K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7.6% | 3,183 | 2,479 | $100K |
| 99177 | 4.9% | 1,890 | 1,886 | $64K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.8% | 763 | 763 | $63K |
| 92587 | 4.7% | 2,009 | 1,994 | $62K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.2% | 647 | 646 | $54K |
| 99188 | 3.4% | 1,700 | 1,697 | $44K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.0% | 435 | 435 | $40K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.4% | 3,424 | 3,390 | $32K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 352 | 330 | $28K |
| 90461 | 2.1% | 957 | 954 | $27K |
26 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.6% | 1,881 | $20K |
| 96127 | 1.5% | 1,751 | $20K | |
| 99401 | 1.1% | 450 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 619 | $7K |
| 81002 | <1% | 2,165 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 330 | $5K |
| 94664 | <1% | 334 | $5K | |
| 96160 | <1% | 1,122 | $4K | |
| 94760 | <1% | 1,755 | $4K | |
| 99051 | <1% | 221 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 176 | $4K |
| 92567 | <1% | 242 | $3K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 353 | $3K |
| 88738 | <1% | 453 | $2K | |
| 0071A | <1% | 43 | $2K | |
| 94761 | <1% | 293 | $1K | |
| 83655 | <1% | 82 | $996.82 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 30 | $946.52 |
| 36416 | <1% | 95 | $712.50 | |
| 0072A | <1% | 15 | $688.20 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 27 | $633.51 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 251 | $615.67 |
| 0051A | <1% | 12 | $432.00 | |
| 99173 | <1% | 18 | $399.96 | |
| 85018 | <1% | 151 | $352.60 | |
| 99070 | <1% | 29 | $72.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.